These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 16826218

  • 1. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M.
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H, Khayat D, Giaccone G, Facon T.
    Cancer; 2005 Nov 01; 104(9):1794-807. PubMed ID: 16178003
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
    Jackson G, Einsele H, Moreau P, Miguel JS.
    Cancer Treat Rev; 2005 Dec 01; 31(8):591-602. PubMed ID: 16298074
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG, Anderson KC.
    Clin Adv Hematol Oncol; 2003 Oct 01; 1(10):596-600. PubMed ID: 16258456
    [Abstract] [Full Text] [Related]

  • 6. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC.
    Expert Rev Anticancer Ther; 2005 Jun 01; 5(3):465-76. PubMed ID: 16001954
    [Abstract] [Full Text] [Related]

  • 7. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA.
    J Natl Compr Canc Netw; 2004 Nov 01; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bortezomib and its role in the management of patients with multiple myeloma.
    Orlowski RZ.
    Expert Rev Anticancer Ther; 2004 Apr 01; 4(2):171-9. PubMed ID: 15056047
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J, Cibeira MT, Rosiñol L.
    Acta Oncol; 2005 Apr 01; 44(5):440-8. PubMed ID: 16118077
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R, Davidson T.
    Oncology (Williston Park); 2004 Dec 01; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The role of proteasome in malignant diseases.
    Moran E, Nencioni A.
    J BUON; 2007 Sep 01; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [Abstract] [Full Text] [Related]

  • 17. Proteasome inhibitors as therapeutics.
    Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC.
    Essays Biochem; 2005 Sep 01; 41():205-18. PubMed ID: 16250907
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS.
    Hawaii Med J; 2008 Sep 01; 67(9):247-9. PubMed ID: 18853901
    [Abstract] [Full Text] [Related]

  • 20. Expanding role of bortezomib in multiple myeloma: nursing implications.
    Colson K, Doss DS, Swift R, Tariman J.
    Cancer Nurs; 2008 Sep 01; 31(3):239-49. PubMed ID: 18453881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.